<DOC>
	<DOC>NCT02427243</DOC>
	<brief_summary>To assess the relative bioavailability and tolerability of two different formulations of crenezumab in approximately 60 healthy volunteers.</brief_summary>
	<brief_title>A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Healthy male or female 18 to 65 years of age at Screening, inclusive Body mass index (BMI) 18.5 to 32 kg/m^2, inclusive Body weight 50 to 100 kg, inclusive Females must be of nonchildbearing potential Males of reproductive potential must agree to remain abstinent or must be using highly effective contraception and must avoid sperm donation, from Screening until at least 8 weeks after the last study drug administration or until study completion, whichever is later Significant medical history, psychiatric disorder, or acute infection at Screening (as determined by Investigator) History of alcoholism or drug addiction within 6 months prior to CRU Checkin Use of tobacco or nicotinecontaining products from 6 months prior to CRU Checkin and during the study Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred wtihin 30 days or 5 halflives, whichever is longer, prior to CRU Checkin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>